

# **Ocular Immunosuppressants Market Forecasts to 2030 – Global Analysis By Drug Class (Calcineurin Inhibitors, Corticosteroids, Monoclonal Antibodies, Janus Kinase (JAK) Inhibitors, Antimetabolites, and Other Drug Classes), Route of Administration, Distribution Channel, Therapeutic Application, End User and By Geography**

<https://marketpublishers.com/r/OBE21C9821BEEN.html>

Date: January 2025

Pages: 150

Price: US\$ 4,150.00 (Single User License)

ID: OBE21C9821BEEN

## **Abstracts**

According to Statistics MRC, the Global Ocular Immunosuppressants Market is accounted for \$4866.99 million in 2024 and is expected to reach \$9453.21 million by 2030 growing at a CAGR of 11.7% during the forecast period. Ocular immunosuppressants are a class of drugs used to manage inflammatory eye conditions by suppressing the immune system's activity. These medications are primarily employed to treat diseases like uveitis, dry eye disease, and corneal graft rejection, where the immune system causes tissue damage. Ocular immunosuppressants help reduce inflammation, prevent immune cell activation, and maintain ocular health.

According to an article updated by the NCBI in April 2022, around 2.5 million people worldwide have multiple sclerosis, and the article also stated that females are three times more prone to develop the illness than males.

Market Dynamics:

Driver:

Increasing prevalence of ocular inflammatory diseases

The growing incidence of ocular inflammatory disorders is a key factor driving the expansion of the ocular immunosuppressants market. Conditions like uveitis, dry eye disease, and corneal graft rejection are becoming more common due to factors such as aging populations, rising autoimmune disorders, and environmental factors. Uveitis, in particular, is a leading cause of blindness if left untreated, while dry eye disease affects a substantial portion of the population worldwide. As these conditions require long-term management to prevent vision loss, the demand for effective immunosuppressive treatments to control inflammation and immune responses is steadily rising, propelling market growth.

#### Restraint:

##### High treatment costs

Biologics and monoclonal antibodies, in particular, are among the most expensive treatments, making them inaccessible to many patients, especially those living in low-income areas. Healthcare systems, insurance companies, and people may all be financially impacted by the expense of these therapies. Patient outcomes are impacted by this affordability barrier, which frequently results in under treatment or delays in receiving therapy. Therefore, even though ocular immunosuppressants are successful in treating severe and chronic ocular inflammatory disorders, their high cost continues to be a major barrier.

#### Opportunity:

##### Increased research and clinical trials

By promoting the creation of innovative and more potent medicines, more research and clinical studies are driving the market expansion for ocular immunosuppressants. Ongoing studies are exploring innovative drug formulations, targeted biologics, and novel delivery systems to address unmet needs in managing ocular inflammatory diseases. Clinical trials are also focusing on improving the safety profile of these treatments, minimizing side effects, and enhancing patient compliance. As new therapies emerge from research, they hold the potential to expand treatment options, improve outcomes, and ultimately drive market growth by providing more tailored and effective solutions for patients with chronic eye conditions.

#### Threat:

## Lack of standardized treatment protocols

Patient outcomes are inconsistent due to variations in treatment philosophies among various institutions and geographical areas. Although ocular immunosuppressants are essential for treating diseases such as ocular graft-versus-host disease and uveitis, effectiveness of therapy is questionable due to varying medical recommendations, patient reactions, and off-label prescription use. The lack of standardized procedures could impede market expansion by decreasing the adoption of new treatments as medical practitioners look for more dependable, scientifically supported remedies.

## Covid-19 Impact

The COVID-19 pandemic had a mixed impact on the ocular immunosuppressants market. On one hand, lockdowns and restrictions led to disruptions in elective eye surgeries and routine ophthalmic care, resulting in delayed treatments for conditions like uveitis and corneal transplants. On the other hand, the pandemic heightened awareness of immune-related disorders, leading to an increased focus on managing ocular inflammatory diseases. Additionally, the shift to telemedicine accelerated the adoption of remote consultations, influencing how ocular conditions are managed.

The corticosteroids segment is expected to be the largest during the forecast period

The corticosteroids segment is estimated to be the largest, due to their proven efficacy in managing inflammation associated with various ocular conditions, such as uveitis and dry eye disease. They offer rapid symptom relief and are widely used in both acute and chronic cases. The availability of corticosteroids in multiple formulations—such as eye drops, oral tablets, and injectables—enhances their versatility and accessibility. Additionally, they are a popular option for treating ocular inflammation worldwide because to their affordability compared to more modern biologics.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the highest CAGR during the forecast period, due to The rise in ocular diseases like uveitis, age-related macular degeneration, and post-transplant complications has led hospitals to focus on advanced therapies to improve patient outcomes and reduce vision loss. The demand for personalized medicine and novel immunosuppressant formulations encourages hospitals to incorporate these treatments, with advances in targeted therapies, better patient management, and specialized ophthalmic care further boosting their use.

### Region with largest share:

Asia Pacific is expected to have the largest market share during the forecast period due to rapidly aging population, increasing incidence of ocular diseases like uveitis and diabetic retinopathy, and improving healthcare infrastructure. Growing awareness of eye health and expanding access to advanced treatments are also contributing to market growth. Additionally, rising healthcare spending and the adoption of innovative therapies, including biologics and corticosteroids, are boosting demand. As the healthcare systems in the region develop, the market for ocular immunosuppressants continues growing.

### Region with highest CAGR:

During the forecast period, the North America region is anticipated to register the highest CAGR, fuelled by a high prevalence of ocular inflammatory diseases such as uveitis, dry eye disease, and age-related macular degeneration. The region benefits from advanced healthcare infrastructure, widespread access to new therapies, and strong awareness of eye health. Robust research and development in ophthalmic immunosuppressants, along with growing adoption of biologics and corticosteroids, are also key factors driving market growth in North America.

### Key players in the market

Some of the key players profiled in the Ocular Immunosuppressants Market include Novartis, AbbVie, Johnson & Johnson, Pfizer, Roche, Bayer, Santen Pharmaceutical Co., Ltd., Astellas Pharma, Allergan, Teva Pharmaceuticals, Regeneron Pharmaceuticals, Merck & Co., Sanofi, UCB Pharma, Horizon Therapeutics, Bausch + Lomb, Biogen, GlaxoSmithKline (GSK), EyePoint Pharmaceuticals, and Nicox.

### Key Developments:

In February 2024, AbbVie Inc. and OSE Immunotherapeutics SA announced a collaboration to advance OSE-230, a monoclonal antibody aimed at treating chronic and severe inflammation. Currently in the preclinical stage, OSE-230 is designed to address persistent inflammatory conditions, with the potential to become a novel immunosuppressive therapy.

In May 2023, a drug from Bausch + Lomb, approved by the FDA to treat dry eye

disease, can now be prescribed to millions of patients whose eyes simply cannot remain wet and lubricated.

In September 2021, AbbVie formed a partnership with REGENXBIO Inc. to develop and bring to market RGX-314, a gene therapy that targets diseases such as wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR).

#### Drug Classes Covered:

Calcineurin Inhibitors

Corticosteroids

Monoclonal Antibodies

Janus Kinase (JAK) Inhibitors

Antimetabolites

Other Drug Classes

#### Route of Administrations Covered:

Topical

Injectable

Oral

Intravitreal Injections

#### Distribution Channels Covered:

Direct Sales

Retail Pharmacies

## Online Pharmacies

### Therapeutic Applications Covered:

Graft Rejection (Post-Transplant)

Dry Eye Disease

Uveitis

Age-related Macular Degeneration (AMD)

Diabetic Retinopathy and Retinal Disorders

Other Inflammatory Eye Disorders

### End Users Covered:

Hospitals

Clinics

Ambulatory Surgical Centers (ASCs)

Retail Pharmacies

Other End Users

### Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

## Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

## Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

## Contents

### **1 EXECUTIVE SUMMARY**

### **2 PREFACE**

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
  - 2.4.1 Data Mining
  - 2.4.2 Data Analysis
  - 2.4.3 Data Validation
  - 2.4.4 Research Approach
- 2.5 Research Sources
  - 2.5.1 Primary Research Sources
  - 2.5.2 Secondary Research Sources
  - 2.5.3 Assumptions

### **3 MARKET TREND ANALYSIS**

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19

### **4 PORTERS FIVE FORCE ANALYSIS**

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

### **5 GLOBAL OCULAR IMMUNOSUPPRESSENTS MARKET, BY DRUG CLASS**

- 5.1 Introduction
- 5.2 Calcineurin Inhibitors
- 5.3 Corticosteroids
- 5.4 Monoclonal Antibodies
- 5.5 Janus Kinase (JAK) Inhibitors
- 5.6 Antimetabolites
- 5.7 Other Drug Classes

## **6 GLOBAL OCULAR IMMUNOSUPPRESENTS MARKET, BY ROUTE OF ADMINISTRATION**

- 6.1 Introduction
- 6.2 Topical
- 6.3 Injectable
- 6.4 Oral
- 6.5 Intravitreal Injections

## **7 GLOBAL OCULAR IMMUNOSUPPRESENTS MARKET, BY DISTRIBUTION CHANNEL**

- 7.1 Introduction
- 7.2 Direct Sales
- 7.3 Retail Pharmacies
- 7.4 Online Pharmacies

## **8 GLOBAL OCULAR IMMUNOSUPPRESENTS MARKET, BY THERAPEUTIC APPLICATION**

- 8.1 Introduction
- 8.2 Graft Rejection (Post-Transplant)
- 8.3 Dry Eye Disease
- 8.4 Uveitis
- 8.5 Age-related Macular Degeneration (AMD)
- 8.6 Diabetic Retinopathy and Retinal Disorders
- 8.7 Other Inflammatory Eye Disorders

## **9 GLOBAL OCULAR IMMUNOSUPPRESENTS MARKET, BY END USER**

- 9.1 Introduction
- 9.2 Hospitals
- 9.3 Clinics
- 9.4 Ambulatory Surgical Centers (ASCs)
- 9.5 Retail Pharmacies
- 9.6 Other End Users

## **10 GLOBAL OCULAR IMMUNOSUPPRESSANTS MARKET, BY GEOGRAPHY**

- 10.1 Introduction
- 10.2 North America
  - 10.2.1 US
  - 10.2.2 Canada
  - 10.2.3 Mexico
- 10.3 Europe
  - 10.3.1 Germany
  - 10.3.2 UK
  - 10.3.3 Italy
  - 10.3.4 France
  - 10.3.5 Spain
  - 10.3.6 Rest of Europe
- 10.4 Asia Pacific
  - 10.4.1 Japan
  - 10.4.2 China
  - 10.4.3 India
  - 10.4.4 Australia
  - 10.4.5 New Zealand
  - 10.4.6 South Korea
  - 10.4.7 Rest of Asia Pacific
- 10.5 South America
  - 10.5.1 Argentina
  - 10.5.2 Brazil
  - 10.5.3 Chile
  - 10.5.4 Rest of South America
- 10.6 Middle East & Africa
  - 10.6.1 Saudi Arabia
  - 10.6.2 UAE
  - 10.6.3 Qatar
  - 10.6.4 South Africa

10.6.5 Rest of Middle East & Africa

## **11 KEY DEVELOPMENTS**

11.1 Agreements, Partnerships, Collaborations and Joint Ventures

11.2 Acquisitions & Mergers

11.3 New Product Launch

11.4 Expansions

11.5 Other Key Strategies

## **12 COMPANY PROFILING**

12.1 Novartis

12.2 AbbVie

12.3 Johnson & Johnson

12.4 Pfizer

12.5 Roche

12.6 Bayer

12.7 Santen Pharmaceutical Co., Ltd.

12.8 Astellas Pharma

12.9 Allergan

12.10 Teva Pharmaceuticals

12.11 Regeneron Pharmaceuticals

12.12 Merck & Co.

12.13 Sanofi

12.14 UCB Pharma

12.15 Horizon Therapeutics

12.16 Bausch + Lomb

12.17 Biogen

12.18 GlaxoSmithKline (GSK)

12.19 EyePoint Pharmaceuticals

12.20 Nicox

## List Of Tables

### LIST OF TABLES

Table 1 Global Ocular Immunosuppressants Market Outlook, By Region (2022-2030) (\$MN)

Table 2 Global Ocular Immunosuppressants Market Outlook, By Drug Class (2022-2030) (\$MN)

Table 3 Global Ocular Immunosuppressants Market Outlook, By Calcineurin Inhibitors (2022-2030) (\$MN)

Table 4 Global Ocular Immunosuppressants Market Outlook, By Corticosteroids (2022-2030) (\$MN)

Table 5 Global Ocular Immunosuppressants Market Outlook, By Monoclonal Antibodies (2022-2030) (\$MN)

Table 6 Global Ocular Immunosuppressants Market Outlook, By Janus Kinase (JAK) Inhibitors (2022-2030) (\$MN)

Table 7 Global Ocular Immunosuppressants Market Outlook, By Antimetabolites (2022-2030) (\$MN)

Table 8 Global Ocular Immunosuppressants Market Outlook, By Other Drug Classes (2022-2030) (\$MN)

Table 9 Global Ocular Immunosuppressants Market Outlook, By Route of Administration (2022-2030) (\$MN)

Table 10 Global Ocular Immunosuppressants Market Outlook, By Topical (2022-2030) (\$MN)

Table 11 Global Ocular Immunosuppressants Market Outlook, By Injectable (2022-2030) (\$MN)

Table 12 Global Ocular Immunosuppressants Market Outlook, By Oral (2022-2030) (\$MN)

Table 13 Global Ocular Immunosuppressants Market Outlook, By Intravitreal Injections (2022-2030) (\$MN)

Table 14 Global Ocular Immunosuppressants Market Outlook, By Distribution Channel (2022-2030) (\$MN)

Table 15 Global Ocular Immunosuppressants Market Outlook, By Direct Sales (2022-2030) (\$MN)

Table 16 Global Ocular Immunosuppressants Market Outlook, By Retail Pharmacies (2022-2030) (\$MN)

Table 17 Global Ocular Immunosuppressants Market Outlook, By Online Pharmacies (2022-2030) (\$MN)

Table 18 Global Ocular Immunosuppressants Market Outlook, By Therapeutic

Application (2022-2030) (\$MN)

Table 19 Global Ocular Immunosuppressants Market Outlook, By Graft Rejection (Post-Transplant) (2022-2030) (\$MN)

Table 20 Global Ocular Immunosuppressants Market Outlook, By Dry Eye Disease (2022-2030) (\$MN)

Table 21 Global Ocular Immunosuppressants Market Outlook, By Uveitis (2022-2030) (\$MN)

Table 22 Global Ocular Immunosuppressants Market Outlook, By Age-related Macular Degeneration (AMD) (2022-2030) (\$MN)

Table 23 Global Ocular Immunosuppressants Market Outlook, By Diabetic Retinopathy and Retinal Disorders (2022-2030) (\$MN)

Table 24 Global Ocular Immunosuppressants Market Outlook, By Other Inflammatory Eye Disorders (2022-2030) (\$MN)

Table 25 Global Ocular Immunosuppressants Market Outlook, By End User (2022-2030) (\$MN)

Table 26 Global Ocular Immunosuppressants Market Outlook, By Hospitals (2022-2030) (\$MN)

Table 27 Global Ocular Immunosuppressants Market Outlook, By Clinics (2022-2030) (\$MN)

Table 28 Global Ocular Immunosuppressants Market Outlook, By Ambulatory Surgical Centers (ASCs) (2022-2030) (\$MN)

Table 29 Global Ocular Immunosuppressants Market Outlook, By Retail Pharmacies (2022-2030) (\$MN)

Table 30 Global Ocular Immunosuppressants Market Outlook, By Other End Users (2022-2030) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

## I would like to order

Product name: Ocular Immunosuppressants Market Forecasts to 2030 – Global Analysis By Drug Class (Calcineurin Inhibitors, Corticosteroids, Monoclonal Antibodies, Janus Kinase (JAK) Inhibitors, Antimetabolites, and Other Drug Classes), Route of Administration, Distribution Channel, Therapeutic Application, End User and By Geography

Product link: <https://marketpublishers.com/r/OBE21C9821BEEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OBE21C9821BEEN.html>